Merck has announced its latest merger plans as the pharmaceutical consolidation spree continues.
According to reports, Merck is set to acquire Cubist Pharmaceuticals for $8.4 billion. The takeover would boost Merck’s operations in antibiotic research as the medical community focuses more on so-called “superbugs.”
Warnings from the World Health Organization have called for renewed collaboration to fight the rise in superbugs.
In a statement, Cubist said it is clear that Merck shares its “commitment to addressing the growing, global problem we are facing” regarding antibiotic resistance.
Full content: CSMonitor
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Apple Faces Contempt Hearings Over App Store Reforms
May 19, 2024 by
CPI
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI